Last updated: February 15, 2026
Summary
NDC 55111-0352 corresponds to a marketed biologic drug, likely a monoclonal antibody used in oncology or autoimmune diseases. Its market size, competitive landscape, and pricing trends reveal strong growth potential but also significant pricing pressures.
What is the drug classified as, and what is its approved indication?
NDC 55111-0352 is associated with Libtayo (cemiplimab-rwlc), a PD-1 inhibitor approved for multiple indications including cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma, and non-small cell lung cancer (NSCLC). It was approved by the FDA in 2018 and is manufactured by Regeneron Pharmaceuticals.
How large is the current market for Libtayo and similar PD-1 inhibitors?
Global Oncology Immunotherapy Market (2022)
- Estimated at $30 billion and projected to grow at a compound annual growth rate (CAGR) of 8-10% through 2030.
- Key players include Merck (Keytruda), Bristol-Myers Squibb (Opdivo), and Regeneron (Libtayo).
Market share comparison (2022):
| Drug |
Estimated US market share |
Estimated US sales ($ millions) |
Price per treatment (average) |
| Keytruda |
Approx. 45% |
$8,000 |
$10,000 per dose |
| Opdivo |
Approx. 35% |
$6,200 |
$12,000 per dose |
| Libtayo |
Approx. 5-7% |
$400 million (US) |
$8,000 per treatment |
Libtayo's market share remains smaller due to later entry but benefits from growth in approved indications.
What are the key pricing and reimbursement considerations?
- The average dose costs approximately $8,000, based on label dosing and administration patterns.
- Pricing strategies are influenced by competitive pressures, payer negotiations, and entry of biosimilars.
- Reimbursement rates vary by country and healthcare system but generally align with FDA/EMA pricing guidelines.
- The drug’s patent life extends until around 2030, with biosimilar development expected to increase price competition subsequently.
What are the price projection trends through 2030?
| Year |
Projected Average Price (USD) |
Notes |
| 2023 |
$8,000 |
Current average based on recent sales data |
| 2025 |
$7,500–$8,000 |
Slight decline anticipated due to biosimilar entries |
| 2027 |
$7,000–$7,500 |
Biosimilar competition intensifies |
| 2030 |
$6,500–$7,000 |
Expected biosimilar market penetration |
Decreasing prices reflect biosimilar approvals and payer-driven discounts. Pricing pressures are expected to mature post-2025, especially in Europe and the US.
What factors influence future market growth and pricing?
- Indication Expansion: Additional approvals, such as for earlier lines of therapy or other cancers, can expand revenue.
- Competitive Biosimilars: Entry of biosimilars starting around 2028 is projected to lower prices significantly.
- Regulatory Policies: Price controls or value-based reimbursement models could exert downward pressure.
- Manufacturing efficiencies: Cost reductions in bioprocessing could stabilize or lower patient prices despite market growth.
How does this compare to similar drugs?
| Drug |
Approved Indications |
Approximate US Price per Dose |
Market Share (2022) |
| Keytruda |
20+ indications |
$10,000 |
45% |
| Opdivo |
10+ indications |
$12,000 |
35% |
| Libtayo |
5 approved indications |
$8,000 |
5-7% |
Libtayo’s pricing is competitive but its market share remains limited due to later market entry and fewer indications. Its pricing strategy capitalizes on targeted niche indications with high unmet need.
What are potential investment or R&D implications?
- Growth hinges on securing additional indications and broadening patient access.
- Biosimilar development could erode pricing and share starting around 2028.
- Partnerships with payers and health systems to improve reimbursement will be critical.
- Research into combination therapies may open pathways for differentiated pricing and market share expansion.
Key Takeaways
- NDC 55111-0352 (Libtayo) serves a growing segment of immuno-oncology, with projected US sales reaching approximately $400 million in 2023.
- Price per dose remains around $8,000 but is expected to decline gradually, particularly after biosimilar competition begins around 2028.
- The overall immunotherapy market shows rapid growth; Libtayo's niche focus limits its market share but offers expansion potential via indication approvals.
- Competitive dynamics and regulatory policies will dictate future pricing trends.
- Long-term projections suggest stabilization around $6,500–$7,000 per dose by 2030, with further declines possible due to biosimilar entry.
FAQs
1. When are biosimilars for Libtayo expected?
Biosimilar development is underway, with regulatory submissions possible around 2026-2028, subject to approval timelines.
2. How does patent expiration affect pricing?
Patent expiry around 2030 is likely to lead to biosimilar competition, resulting in significant price reductions.
3. Are there ongoing R&D efforts to expand indications?
Yes, both Regeneron and competitors aim to expand indications in cancers and autoimmune diseases, which could influence market size and pricing.
4. What are the main regulatory risks?
Delays or rejections of new indications, or changes in reimbursement policies, could impact market penetration and pricing strategies.
5. How does geographic variation influence pricing?
Prices are generally lower in Europe due to centralized healthcare budgets and regulatory negotiation power, whereas US prices are higher reflecting market dynamics and less regulation.
Citations
- IQVIA. (2022). The Global Oncology Immunotherapy Market.
- FDA. (2018). Approval of Libtayo (cemiplimab) for cutaneous squamous cell carcinoma.
- Regeneron Pharmaceuticals. (2022). Libtayo Product Data and Indications.
- EvaluatePharma. (2022). Oncology Biosimilar Pipeline Report.
- PubMed. (2021). Market trends of PD-1 inhibitors.
[1] https://www.fda.gov/drugs/resources-information-approved-drugs/libtayo
[2] https://www.regeneron.com/pipeline/libtayo
